858 Therapeutics Inc. has patented a series of 6,6-fused heterocyclic compounds acting as N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of acute myeloid leukemia.
858 Therapeutics Inc. emerged from stealth mode, unveiling $60 million in series A funding and plans to drug a series of protein targets involved in modulating RNA biology in cancer.